Gastrointestinal (GI) problems, liver dysfunction, skin rashes, and other symptoms can develop as acute (temporary) GVHD within 100 days of a transplant or as chronic GVHD months — or even years ...

Steroid therapy is the first-line treatment for graft-versus-host disease (GVHD). If GVHD does not respond to initial therapies, doctors may consider chemotherapy, monoclonal antibodies ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

The efficacy of IVIG in preventing GvHD has not been definitely demonstrated clinically. Using a xenogeneic model of GvHD in NOD/SCID/γc− (NSG) mice, we showed that weekly administration of ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

Bioheng Therapeutics’ IND application for CTD402 gets US FDA clearance for CD7 UCAR T cell therapy in T-cell acute lymphoblastic leukemia: Boston Friday, March 7, 2025, 16:00 Hr ...

The BLA is based on data from an open label, single-arm Phase III study, which evaluated remestemcel-L in 55 pediatric patients who had failed to respond to prior steroid treatment for acute GvHD.

It is genetically modified to avoid fratricide, graft-versus-host disease (GvHD), and host-versus-graft rejection (HvG) while enhancing anti-tumor activity. CTD402 can be prepared in a single ...